Artelo BiosciencesARTL -1.75%31 Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus rates ARTL with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 151 Biotechnology companies, Artelo Biosciences ranks worse than 662250.99% on this metric.
As of today (2026-06-26), the Trailing Annual Dividend Yield of Artelo Biosciences is 0.00%.
The historical rank and industry rank for Artelo Biosciences's Dividend Yield % or its related term are showing as below:
ARTL's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.53 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Artelo Biosciences Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Artelo Biosciences's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARTL vs RNAZ, GLMD, DCOY: Dividend Yield % Comparison
For the Biotechnology subindustry, Artelo Biosciences's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's Dividend Yield % falls into.
Artelo Biosciences (ARTL) has a Dividend Yield % of 0.00% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Artelo Biosciences and its competitors. According to the industry distribution chart, Artelo Biosciences ranks #999999 out of 151 companies in the Biotechnology industry.
Is Artelo Biosciences' Dividend Yield % too high?
Artelo Biosciences' current Dividend Yield % is 0.00%. Based on the distribution chart, Artelo Biosciences ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Artelo Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' Dividend Yield % compare to RNAZ and GLMD?
According to the Biotechnology industry distribution chart, Artelo Biosciences ranks #999999 out of 151 companies for Dividend Yield %. This places Artelo Biosciences in the lower half of its industry. The industry median Dividend Yield % is 1.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.53, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Artelo Biosciences and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artelo Biosciences's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Artelo Biosciences' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
31GF Score
Get the complete analysis for ARTL
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTL has been successfully added to your 
